Century Therapeutics, Inc. IPSC
We take great care to ensure that the data presented and summarized in this overview for Century Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IPSC
View all-
Vr Adviser, LLC New York, NY3.41MShares$10.7 Million1.22% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$10.1 Million1.08% of portfolio
-
Boxer Capital, LLC San Diego, CA1.75MShares$5.51 Million0.38% of portfolio
-
Black Rock Inc. New York, NY1.5MShares$4.72 Million0.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.31MShares$4.12 Million1.32% of portfolio
-
Avidity Partners Management LP Dallas, TX1.22MShares$3.85 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.14MShares$3.59 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA900KShares$2.84 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY797KShares$2.51 Million0.04% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA615KShares$1.94 Million0.01% of portfolio
Latest Institutional Activity in IPSC
Top Purchases
Top Sells
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at IPSC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.77%
|
$10,000
$2.84 P/Share
|
|
Jun 07
2024
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
17,007
+4.84%
|
-
|
|
Jun 05
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.74%
|
$15,000
$3.0 P/Share
|
|
May 20
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.71%
|
$15,000
$3.0 P/Share
|
|
May 06
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.68%
|
$15,000
$3.12 P/Share
|
|
May 03
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
913
-0.66%
|
$2,739
$3.11 P/Share
|
|
May 03
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
257
-0.08%
|
$771
$3.11 P/Share
|
|
Apr 22
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.65%
|
$15,000
$3.1 P/Share
|
|
Mar 07
2024
|
Brent Pfeiffenberger President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,425
+1.17%
|
-
|
|
Mar 07
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+14.8%
|
-
|
|
Mar 07
2024
|
Gregory Russotti Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+7.35%
|
-
|
|
Mar 07
2024
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+4.22%
|
-
|
|
Mar 07
2024
|
Hyam Levitsky President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+50.0%
|
-
|
|
Mar 07
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
22,831
-16.67%
|
$114,155
$5.14 P/Share
|
|
Mar 07
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,831
+14.29%
|
$22,831
$1.03 P/Share
|
|
Mar 06
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
30,684
-21.19%
|
$122,736
$4.96 P/Share
|
|
Mar 06
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,684
+17.48%
|
$30,684
$1.03 P/Share
|
|
Feb 16
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
485
-0.42%
|
$1,940
$4.86 P/Share
|
|
Feb 16
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+0.42%
|
$485
$1.03 P/Share
|
|
Feb 06
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,784
-1.54%
|
$7,136
$4.49 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.57M shares |
|---|---|
| Exercise of conversion of derivative security | 54K shares |
| Payment of exercise price or tax liability | 37.4K shares |
|---|---|
| Open market or private sale | 85.2K shares |